European Medicines Agency Fast-Tracks Review of Revolution Medicines' Experimental Pancreatic Cancer Pill

The European Medicines Agency (EMA) has started a fast-track "rolling review" for Revolution Medicines' experimental pill, daraxonrasib, for patients with metastatic pancreatic cancer. The decision follows a late-stage study and addresses a significant unmet need, as these patients have a life expectancy of about six months. The U.S. FDA also granted the drug early access in May 2026.

EMA rolling review process

• ▪The EMA's rolling review process allows its Committee for Medicinal Products for Human Use to evaluate data as it becomes available before a formal marketing application.
• ▪The European Medicines Agency (EMA) began a rolling review of Revolution Medicines' experimental drug, daraxonrasib, on July 7, 2026.
• ▪While a rolling review can shorten the overall assessment timeline, medicines are held to the same standards as those in a conventional review.

Daraxonrasib clinical development

• ▪The EMA's decision to start the review was based on results from a late-stage study comparing daraxonrasib with chemotherapy in previously treated patients.
• ▪Daraxonrasib is being studied for metastatic pancreatic ductal adenocarcinoma, a cancer that has spread and for which patients have already received other therapies.

Metastatic pancreatic cancer treatment

• ▪The life expectancy for previously treated metastatic pancreatic cancer patients is about six months, according to the EMA.
• ▪Patients with metastatic pancreatic cancer whose disease progresses after initial treatment have limited therapeutic options and a poor prognosis.

Regulatory fast-track designations

• ▪In May 2026, the U.S. FDA authorized early access to daraxonrasib for patients with previously treated pancreatic cancer.
• ▪Daraxonrasib was designated a high-priority medicine under the EMA's Cancer Medicines Pathfinder program.
• ▪The EMA's Cancer Medicines Pathfinder program supports treatments that could address significant unmet medical needs.

1 source